Get MoonLake Immunotherapeutics alerts:MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) – Research analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, September 29th. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.51) EPS, FY2026 earnings at ($4.06) EPS, FY2027 earnings at ($4.47) EPS, FY2028 earnings at ($3.68) EPS and FY2029 earnings at ($1.24) EPS. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. Featured ArticlesReceive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.